Real-world experience of metformin 1000 mg/day in patients with type 2 diabetes mellitus and comorbidities from Myanmar

Soe Yarzar, Myo Lin Aung, Thet Kyaw Soe, Aung Ko Ko Win, Thuzar Lwan Thar, Santosh Revankar, Tripti Sharmaa


Background: The study was conducted to assess the efficacy and safety of 1000 (mg/day) metformin in patients with type 2 diabetes (T2DM) with comorbidities and special reference to elderly people in Myanmar.

Methods: This was a retrospective, post surveillance study conducted in patients diagnosed with T2DM receiving treatment of metformin (1000 mg/day). Baseline characteristics, comorbidities, random blood sugar level (RBS) and RBS changes pre- and post-therapy were retrieved from patient’s medical records. A paired sample t-test was used for comparing the pre- and post-treatment RBS levels.

Results: A total of 303 patients with T2DM were included. A total of 88, 115 and 100 patients belonged to age groups ≤50, >50-≤60 and >61 years, respectively. Duration of T2DM was significantly higher in elderly patients (>61 years) compared to ≤50 and >50-≤60 age group. Hypertension was the most common comorbid condition observed in all age groups followed by cardiovascular disease. However, both hypertension and cardiovascular disease were significantly higher among elderly patients (>61 years) compared to ≤50 and >50-≤60 age group (p<0.001). The mean RBS was significantly reduced at 3 months with metformin treatment in all age groups. However, mean change from baseline was comparatively higher in elderly patients with diabetes (≤50 years, 94.6 mg/dL; >50-≤60 years, 86.2 mg/dL and >61 years, 97.2 mg/dL). Metformin was well tolerated with minimal gastrointestinal adverse events (n=27).

Conclusions: In this post marketing surveillance study, metformin (1000 mg/day) was found to be effective in reducing RBS in T2DM patients with comorbidities especially older adults and well tolerated with no risk of hypoglycemia.


Metformin, Large dose, Random blood sugar, Hypertension, Gastrointestinal

Full Text:



International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes facts and figures. Available at: Accessed on 8 November 2021.

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.

Adelman MW, Kurbatova E, Wang YF, Leonard MK, White N, McFarland DA, et al. Cost analysis of a nucleic acid amplification test in the diagnosis of pulmonary tuberculosis at an urban hospital with a high prevalence of TB/HIV. PloS one. 2014;9:e100649.

Codsi E, Tweet MS, Rose CH, Arendt KW, Best PJ, Hayes SN. Spontaneous Coronary Artery Dissection in Pregnancy: What Every Obstetrician Should Know. Obstetrics and gynecology. 2016;128:731-8.

American Diabetes Association. Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43:S98-110.

Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669-701.

Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5:6.

Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. Nutr Metab Cardiovasc Dis. 2017;27:657-69.

Metformin in the diabetic elderly patient: an old, safe and effective treatment Focus Farmacovigilanza. 2016;93(3):7

Wang CP, Lorenzo C, Espinoza SE. Frailty attenuates the impact of metformin on reducing mortality in older adults with type 2 diabetes. J Endocrinol Diabetes Obes. 2014;2:1031.

Sumantri S, Setiati S, Purnamasari D, Dewiasty E. Relationship between metformin and frailty syndrome in elderly people with type 2 diabetes. Acta Med Indones. 2014;46:183-8.

Rosenstock J. Management of type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging. 2001;18:31-44.

Cho N, Colagiuri S, Distiller L, Dong B, Dunning T, Gadsby R, et al. IDF Working Group. Managing Older People with Type 2 Diabetes. Global Guideline. Brussels, Belgium, International Diabetes Federation. 2013.

Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA. Clinical Guidelines Committee of the American College of Physicians. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann Intern Med. 2018;168:569-76

Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-tomoderate renal insufficiency. Diabetes Care. 2011;34:1431-7.

Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018;34:575-84.

Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157:601-10.

Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6:395-402.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65. Erratum in. Lancet. 1998;352:1558.

Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345-51.

Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583-90.

Aung WP, Bjertness E, Htet AS, Stigum H, Kjøllesdal MKR. Trends in Diabetes Prevalence, Awareness, Treatment and Control in Yangon Region, Myanmar, Between 2004 and 2014, Two Cross-Sectional Studies. Int J Environ Res Public Health. 2019;16:3461.

Lalau JD, Vermersch A, Hary L, Andrejak M, Isnard F, Quichaud J. Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol. 1990;28:329-32.

Schlender L, Martinez YV, Adeniji C, Reeves D, Faller B, Sommerauer C, et al. Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 2017;17(Suppl 1):227.

Solymár M, Ivic I, Pótó L, Hegyi P, Garami A, Hartmann P, et al. Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis. PLoS One. 2018;13:e0207947.

Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes. 2015;64:1786-93.

Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab. 1991;17:224-31.

Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemiain type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006;49:1711-21.